

# INSPIREMD, INC.

## **FORM 8-K** (Current report filing)

Filed 09/12/13 for the Period Ending 09/09/13

Address	321 COLUMBUS AVENUE BOSTON, MA 02116
Telephone	(857) 453-6553
CIK	0001433607
Symbol	NSPR
SIC Code	3841 - Surgical and Medical Instruments and Apparatus
Industry	Medical Equipment & Supplies
Sector	Healthcare
Fiscal Year	12/31

UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT  
Pursuant to Section 13 or 15(d) of the  
Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): September 9, 2013

**InspireMD, Inc.**

(Exact name of registrant as specified in its charter)

Delaware

(State or other jurisdiction of  
incorporation)

001-35731

(Commission File Number)

26-2123838

(IRS Employer Identification No.)

800 Boylston Street, Suite 16041  
Boston, Massachusetts

(Address of principal executive offices)

02199

(Zip Code)

Registrant's telephone number, including area code: (857) 453-6553

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- Pre-commencement communications pursuant to Rule 13e-4 (c) under the Exchange Act (17 CFR 240.13e-4(c))

**Item 8.01 Other Events.**

On September 9, 2013, InspireMD, Inc. issued a press release announcing that it will release its financial results for the fiscal year ended June 30, 2013 on Tuesday, September 17, 2013.

A copy of the press release is attached as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated by reference herein.

**Item 9.01 Financial Statements and Exhibits.**

(d) Exhibits

<u>Exhibit Number</u>	<u>Description</u>
99.1	Press release dated September 9, 2013

---

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

**InspireMD, Inc.**

Date: September 12, 2013

By: /s/ Craig Shore

Name: Craig Shore

Title: Chief Financial Officer

---



## **InspireMD to Report Fiscal Year 2013 Results on September 17<sup>th</sup>**

BOSTON, MA - September 9, 2013 - InspireMD, Inc. (NYSE MKT: NSPR) (“InspireMD” or the “Company”), a leader in embolic protection stents, announced today that it will release its financial results for the fiscal year ended June 30, 2013 on Tuesday, September 17, 2013. The Company will host a conference call on that day at 4:30 p.m. ET to review the Company’s financial results and business outlook.

Participants should call (877) 375-4189 (United States/Canada) or (973) 935-2046 (International) and request the InspireMD call or provide confirmation code 45736242. A live webcast of the call will be available on the Investor Relations section of the Company’s website at [www.inspire-md.com/site\\_en/for-investors/](http://www.inspire-md.com/site_en/for-investors/). Please allow 10 minutes prior to the call to visit this site to download and install any necessary audio software.

A replay of the conference call will be available approximately two hours after completion of the live conference call and will be accessible until 11:59 p.m. ET on October 1, 2013. To listen to the replay, dial (855) 859-2056 (United States/Canada) or (404) 537-3406 (International) and enter code 45736242. The webcast of the event will also be archived for two weeks on the Investor Relations section of the Company's website at [www.inspire-md.com/site\\_en/for-investors/](http://www.inspire-md.com/site_en/for-investors/).

### **About Stenting and MGuard™ EPS**

Standard stents were not engineered for heart attack patients. They were designed for treating stable angina patients, whose occlusion is different from that of an occlusion in a heart attack patient.

In acute heart attack patients, the plaque or thrombus is unstable and often breaks up as the stent is implanted, causing downstream blockages (some of which can be fatal) in a significant portion of heart attack patients.

The MGuard EPS is integrated with a precisely engineered micro net mesh that prevents the unstable arterial plaque and thrombus (clots) that caused the heart attack blockage from breaking off.

While offering superior performance relative to standard stents in STEMI patients with regard to ST segment resolution, the MGuard EPS requires no change in current physician practice – an important factor in promoting acceptance and general use in time-critical emergency settings.

---



**About InspireMD, Inc.**

InspireMD seeks to utilize its proprietary MGuard technology to make its products the industry standard for embolic protection stents and to provide a superior solution to the key clinical issues of current stenting in patients with a high risk of distal embolization, no reflow and major adverse cardiac events.

InspireMD intends to pursue applications of this technology in coronary, carotid and peripheral artery procedures. InspireMD's common stock is quoted on the NYSE MKT under the ticker symbol NSPR.

MGuard EPS is CE Mark approved. It is not approved for sale in the U.S. by the FDA at this time.

**Investor Contacts:**

Todd Fromer / Garth Russell  
KCSA Strategic Communications  
Phone: 212-896-1215 / 212-896-1250  
Email: tfromer@kcsa.com / grussell@kcsa.com

**Media Contacts:**

Lewis Goldberg / Samantha Wolf  
KCSA Strategic Communications  
Phone: 212-896-1216 / 212-896-1220  
Email: lgoldberg@kcsa.com / swolf@kcsa.com

---